Prot #CACZ885D2310: Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients with COVID-19-Induced Pneumonia (CAN-COVID)

Project: Research project

Project Details

StatusFinished
Effective start/end date4/14/20 → 10/31/21

Funding

  • Novartis Pharmaceuticals Corporation (Prot #CACZ885D2310)